Is A Transition In The Making?

(RTTNews) - Shares of Transition Therapeutics Inc. (TTHI) (TTH.TO) have gained nearly 25% in the last one month, as the company awaits phase II study results of its neuropsychiatric drug candidate - ELND005.

ELND005 is under a phase II trial, dubbed Harmony AD Study, being tested as a treatment for agitation and aggression in patients with mild to severe Alzheimer's disease. The Harmony AD Study has enrolled 350 Alzheimer's disease patients at 69 clinical sites in the United States, Canada, Spain and the United Kingdom.

The primary efficacy endpoint of the study is the change from baseline in the Neuropsychiatric Inventory - Clinician ("NPI-C") scale of agitation and aggression.

The top-line data from the Harmony AD Study are expected to be announced early summer 2015.

We alerted our premium subscribers to TTHI on April 6, 2015 when it was trading around $6.75. The stock touched a new 52-week high of $8.67 on June 19, 2015 before closing the day's trading at $8.62.

The clinical trial results are capable of making or breaking the biotech stocks, and it remains to be seen how the ELND005 trial in Alzheimer's disease patients pans out.

Are you following TTHI yet?